Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biocept Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BIOC
Nasdaq
2834
https://biocept.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biocept Inc
Biocept Reports First Quarter 2022 Financial Results
- May 23rd, 2022 8:05 pm
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
- May 16th, 2022 8:05 pm
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 8th, 2022 8:05 pm
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
- Apr 6th, 2022 12:00 pm
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
- Mar 31st, 2022 10:15 pm
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
- Mar 18th, 2022 12:00 pm
Biocept Appoints Philippe Marchand as Chief Operating Officer
- Mar 8th, 2022 1:17 pm
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
- Feb 22nd, 2022 9:17 pm
Biocept, Inc. (NASDAQ:BIOC) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
- Feb 18th, 2022 9:54 am
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
- Feb 16th, 2022 9:05 pm
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
- Feb 10th, 2022 1:17 pm
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
- Jan 21st, 2022 1:00 pm
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?
- Jan 7th, 2022 2:40 pm
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
- Jan 4th, 2022 1:00 pm
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
- Dec 9th, 2021 1:17 pm
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
- Dec 3rd, 2021 11:49 am
Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression
- Nov 22nd, 2021 6:56 pm
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
- Nov 22nd, 2021 1:17 pm
CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
- Nov 18th, 2021 7:45 pm
Biocept Reports Third Quarter 2021 Financial Results
- Nov 15th, 2021 9:05 pm
Scroll